Post by
Golddetector on Aug 03, 2021 9:01pm
QIXLEEF
In my opinion the interim analysis of reborn trials planned in q3 will be one of the main catalysts this year. Even more important than reduvo din and commercialization that will transfer Tbp to revenue generating Pharma in q4. The analysis will present a major threat to a very major industry. I think 1st patient will be done trail next week so we are very close here. Keep in mind that only morphine was used until recently so we might see morphine comparisons first. It will give an indication about the trials against the other two. Positive results will correct market valuation of tbp to new levels. It is multi billion industry so this should be valued accordingly. Hopefully august will bring the good news here. Gl longs
Comment by
DONOOW on Aug 03, 2021 9:16pm
Waiting for tweets or the YouTube channel Wall Street reporter to bring some news.